

# A Post-Authorization Safety Study (PASS) to Characterize Safety Events and Special Conditions, Such as Pregnancy and Infant Outcomes, in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Crovalimab Within the IPIG Registry

**First published:** 07/08/2025

**Last updated:** 13/04/2026

Study

Planned

## Administrative details

### EU PAS number

EUPAS1000000702

---

### Study ID

1000000702

---

### DARWIN EU® study

No

---

### Study countries

- Belgium
  - Canada
  - France
  - Germany
  - Italy
  - Korea, Republic of
  - Netherlands
  - Spain
  - United Kingdom
  - United States
- 

### **Study description**

This study is a multi-center, multi-country, non-interventional, registry-based PASS using secondary data collected as part of the Crovalimab Silo registry (Study MO44987) of participants with PNH exposed to crovalimab, including pregnant women and their infants.

The Crovalimab Silo will encompass retrospective and prospective data from all enrolled participants treated with crovalimab including patients' characteristics and clinical outcomes (including safety data, pregnancy and infant outcomes, and breastfeeding), and crovalimab exposure.

---

### **Study status**

Planned

## Research institutions and networks

### Institutions

# F. Hoffmann-La Roche

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

## Contact details

### Study institution contact

Felipe Castro [global.clinical\\_trial\\_registry@roche.com](mailto:global.clinical_trial_registry@roche.com)

Study contact

[global.clinical\\_trial\\_registry@roche.com](mailto:global.clinical_trial_registry@roche.com)

### Primary lead investigator

Felipe Castro

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned: 01/03/2025

Actual: 26/11/2024

---

### Study start date

Planned: 30/06/2026

---

### Date of final study report

Planned: 30/12/2033

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

F. Hoffmann-La Roche Ltd.

## Study protocol

[Prot\\_MO45473\\_crovalimab\\_v3,\\_Published\\_Output-1\\_Redacted.pdf](#) (988.05 KB)

[Protocol\\_-\\_MO45473\\_-\\_PIASKY\\_-\\_v4\\_-\\_GlobalCore\\_\(1\)\\_Redacted \(1\).pdf](#) (818.81 KB)

## Regulatory

### **Was the study required by a regulatory body?**

Yes

---

### **Is the study required by a Risk Management Plan (RMP)?**

EU RMP category 3 (required)

## Other study registration identification numbers and links

MO45473

## Methodological aspects

## Study type

**Study topic:**

Disease /health condition  
Human medicinal product

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Evaluation of patient-reported outcomes  
Safety study (incl. comparative)

**Data collection methods:**

Secondary use of data

---

**Study design:**

Data for this study will be collected as part of the Crovalimab Silo registry. This encompasses retrospective & prospective data (participants' characteristics, clinical outcomes & crovalimab exposure) for all participants treated with crovalimab, including pregnant participants & their infants.

**Main study objective:**

The aim of this study is to characterize the safety profile of crovalimab in participants with PNH, with a specific focus on adverse events of special interest (AESIs).

This study also aims to assess adverse events (AEs), serious adverse events (SAEs), pregnancy, and infant outcomes in female participants with PNH exposed to crovalimab during pregnancy and through breastfeeding.

## Study Design

## **Non-interventional study design**

Cohort

Other

---

## **Non-interventional study design, other**

Observational post-authorization safety study (PASS)

# Study drug and medical condition

## **Medicinal product name**

PIASKY

---

## **Study drug International non-proprietary name (INN) or common name**

CROVALIMAB

---

## **Anatomical Therapeutic Chemical (ATC) code**

(L04AJ07) crovalimab

crovalimab

---

## **Medical condition to be studied**

Paroxysmal nocturnal haemoglobinuria

# Population studied

## **Short description of the study population**

Participants with PNH who are treated with crovalimab and have available data from the Crovalimab Silo, including participants who are pregnant and information from their infants.

---

## Age groups

- **In utero**
  - **Paediatric Population (< 18 years)**
    - Neonate
      - Preterm newborn infants (0 – 27 days)
      - Term newborn infants (0 – 27 days)
    - Infants and toddlers (28 days – 23 months)
    - Adolescents (12 to < 18 years)
  - **Adult and elderly population (≥18 years)**
    - Adults (18 to < 65 years)
      - Adults (18 to < 46 years)
      - Adults (46 to < 65 years)
    - Elderly (≥ 65 years)
      - Adults (65 to < 75 years)
      - Adults (75 to < 85 years)
      - Adults (85 years and over)
- 

## Special population of interest

Pregnant women

---

## Estimated number of subjects

300

## Study design details

### Setting

Inclusion criteria:

- Participants with PNH confirmed by flow cytometry.
- Participants and/or parent/legally authorized representative provide written

informed consent/assent to participate in the Core Registry and the Crovalimab Silo prior to any registry-related data collection, in a manner approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) and local regulations.

-Participants with PNH currently being treated with or who start crovalimab during the study period.

Exclusion criteria:

-Participants with PNH participating in an interventional PNH clinical trial while receiving crovalimab (i.e., in combination with other therapy), with exception of participants with PNH participating in the extension period of COMMODORE/COMPOSER Roche studies and Post Trial Access Programs.

The exclusion criteria for all participants will also be applicable to assess crovalimab exposure during pregnancy, as well as pregnancy, infant, and breastfeeding outcomes.

---

## **Comparators**

None

---

## **Outcomes**

Primary Outcomes:

-Presence, type, onset and resolution date and hospitalizations of serious infections

-Presence, type, onset and resolution date and hospitalizations of Meningococcal and other infections with encapsulated bacteria

-Development or Worsening of any Neurological Condition

-Presence and type of malignancy, onset and resolution date

-Serious hemolysis events, onset and resolution date

- Serious Hemolysis after crovalimab discontinuation
- Number of transient immune complex reactions
- Number of infusion and injection-related reactions
- Pregnancy-related outcomes [Ectopic pregnancy, spontaneous abortion, pregnancy terminations, fetal death or stillbirth, live birth, preterm birth, preeclampsia, eclampsia, Preterm Prelabor Rupture of Membrane (PPROM)]
- Infant-related outcomes [Size for gestational age, low birth weight, postnatal growth deficiency or failure to thrive (FTT), infant developmental deficiency, congenital malformations, serious and severe infections, and hospitalization of infants
- Number of neonatal deaths, perinatal deaths, infant deaths and maternal deaths
- Any adverse events (AEs) during pregnancy
- Any AEs for lactating females and infants through breastfeeding
- Any AEs experienced by the infant at birth and up to through at least the first year of life

#### Secondary Outcomes:

- AEs and serious adverse events (SAEs) (not included as AESIs)
- Clinical outcome and laboratory test results related to PNH among participants who experienced an AESI
- Fatigue assessment using the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue questionnaire for participants who experienced an AESI

---

#### **Data analysis plan**

Descriptive statistics will be reported using summary tables and figures (where appropriate). Continuous variables will be summarized using mean, standard deviation, median, range (min-max) and interquartile range. Categorical variables will be summarized using counts and proportions (%).

Incidence and incidence rate (IRs; in person-years) and their 95% confidence interval (Cis) of AESIs, SAEs and AEs will be calculated. The exact 95% CIs will be computed using the Clopper-Pearson method.

Incidence proportions will be calculated as the proportion of participants afflicted with each of the AESIs, SAEs, and AEs up to the data extraction date.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data source(s)

The International PNH Interest Group PNH Registry / The IPIG PNH Registry

---

### Data sources (types)

[Disease registry](#)

[Drug registry](#)

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

Unknown